Next Article in Journal
Acute Pharmacological Effects of Two Synthetic Cathinones in Humans: An Observational Study of N-Ethylhexedrone and N-Ethyl-nor-pentedrone
Previous Article in Journal
Using UV–Vis Titration to Elucidate Novel Epigallocatechin Gallate (EGCG)-Induced Binding of the c-MYC G-Quadruplex
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Urbánek et al. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505

1
Centre of Polymer Systems, Tomas Bata University in Zlín, Trida Tomase Bati 5678, 76001 Zlin, Czech Republic
2
LinkoCare Life Sciences AB, 16975 Stockholm, Sweden
3
NaturaLens AB, 58330 Linköping, Sweden
4
Gemini Eye Clinic, U Gemini 360, 76001 Zlin, Czech Republic
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(5), 720; https://doi.org/10.3390/ph18050720
Submission received: 6 May 2025 / Accepted: 8 May 2025 / Published: 14 May 2025

Text Correction

As an addition to the original publication [1], we conducted a supplementary data analysis to clearly reflect the contributions of all team members.
A correction has been made to 2. Results and Discussion, 2.2. Drug Release from the Collagen Carrier, Paragraph 4:
On the other hand, the exponential model with the Korsmeyer–Peppas (KP) component b·tnr [57], where b represents the kinetic constant characteristic of the drug/polymer system, tr is the release time, and n is the diffusional release exponent, fits the data obtained for Levofloxacin with greater accuracy (R2 = 0.99551)—see Figures S17 and S18. The Korsmeyer–Peppas model combined with the first-order exponential model seems to be an appropriate model for more structurally complicated substances and polymer carriers.

Addition of Supplementary Materials

As an addition to the original publication [1], we conducted a supplementary data analysis to clearly reflect the contributions of all team members and updated the Supplementary Materials. The newly added Supplementary Materials part appears below:
Figure S17 Tetracaine release profiles of drug carriers with the kinetic model and its parameters—first-order exponential kinetic model and comparison with the same exponential model including the Korsmeyer–Peppas (KP) component; Figure S18 Levofloxacin release profiles of drug carriers with the kinetic model and its parameters—first-order exponential kinetic model and comparison with the same exponential model including the Korsmeyer–Peppas (KP) component.

Addition of an Author

In the original publication [1], Mehrdad Rafat was not included as an author. Mehrdad Rafat belongs to the new affiliations 2 and 3:
2
LinkoCare Life Sciences AB, 16975 Stockholm, Sweden; mrafat@linkocare.com
3
NaturaLens AB, 58330 Linköping, Sweden
The corrected Author Contributions statement appears here.
Conceptualization: P.U. and I.K.; investigation: P.U., B.H., J.Š., P.Š., T.Š., P.S., M.R. and I.K.; methodology: P.U., P.S. and I.K.; formal analysis P.U., B.H. and I.K.; visualization: P.U., B.H., J.Š. and I.K.; resources: M.R.; data analysis: P.U. and M.R.; writing—original draft: P.U., B.H., P.Š. and I.K.; writing—review and editing: P.U. and I.K.; funding acquisition: P.U., I.K. and P.S. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

In the original publication [1], the Conflicts of Interest statement of Mehrdad Rafat was not included. The updated Conflicts of Interest should read as follows: Author Mehrdad Rafat was employed by the companies LinkoCare Life Sciences AB and NaturaLens AB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Urbánek, P.; Šuly, P.; Ševčík, J.; Hanulíková, B.; Kuřitka, I.; Šopík, T.; Rafat, M.; Stodůlka, P. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Urbánek, P.; Šuly, P.; Ševčík, J.; Hanulíková, B.; Kuřitka, I.; Šopík, T.; Rafat, M.; Stodůlka, P. Correction: Urbánek et al. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505. Pharmaceuticals 2025, 18, 720. https://doi.org/10.3390/ph18050720

AMA Style

Urbánek P, Šuly P, Ševčík J, Hanulíková B, Kuřitka I, Šopík T, Rafat M, Stodůlka P. Correction: Urbánek et al. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505. Pharmaceuticals. 2025; 18(5):720. https://doi.org/10.3390/ph18050720

Chicago/Turabian Style

Urbánek, Pavel, Pavol Šuly, Jakub Ševčík, Barbora Hanulíková, Ivo Kuřitka, Tomáš Šopík, Mehrdad Rafat, and Pavel Stodůlka. 2025. "Correction: Urbánek et al. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505" Pharmaceuticals 18, no. 5: 720. https://doi.org/10.3390/ph18050720

APA Style

Urbánek, P., Šuly, P., Ševčík, J., Hanulíková, B., Kuřitka, I., Šopík, T., Rafat, M., & Stodůlka, P. (2025). Correction: Urbánek et al. Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing. Pharmaceuticals 2023, 16, 505. Pharmaceuticals, 18(5), 720. https://doi.org/10.3390/ph18050720

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop